ACS Appl. Mater. Interfaces:苏州医工所治疗肝癌的多功能纳米载药系统研究获进展

2018-01-30 佚名 苏州生物医学工程技术研究所

近些年来,科学家们发现了光热治疗的热效应可以促进银纳米材料释放银离子。而银离子在细胞内可以产生活性氧自由基,并通过线粒体凋亡途径诱导细胞凋亡。因此,银纳米材料协同光热治疗将是一种高效安全的肿瘤治疗策略。但相关研究面临难题和挑战,一是如何将光敏剂 ICG 和银纳米材料同时输送到肿瘤组织以增加癌症的治疗效果,二是如何开发一种开关去调控银离子的释放与 ICG 的剂量以增加治疗的安全性,三是如何提高其对肿

光热治疗是一种利用光敏剂吸收近红外光,并将光能转化为热能,进而杀死肿瘤细胞的物理治疗模式,具有简易可控的治疗模式和极高的生物安全性,是目前相关研究领域的热点问题。其光敏剂包括金纳米材料、硫化铜、碳点以及一些有机的近红外光染料。其中,吲哚箐绿(ICG)由于其高的光热转化效率、低的细胞毒性以及出色的近红外光成像效果,而具有极大的临床转化潜力。但 ICG 在体内易被降解,并且在治疗癌症的过程中缺少对肿瘤组织的特异性。因此,它的临床应用受到限制。此外,光热治疗虽然是一种安全有效的肿瘤治疗模式,但单一的光热治疗不足以完全地消灭肿瘤组织。光热治疗应结合其他治疗模式,通过多种治疗模式的协同作用,提高对肿瘤组织的杀伤。近些年来,科学家们发现了光热治疗的热效应可以促进银纳米材料释放银离子。而银离子在细胞内可以产生活性氧自由基,并通过线粒体凋亡途径诱导细胞凋亡。因此,银纳米材料协同光热治疗将是一种高效安全的肿瘤治疗策略。但相关研究面临难题和挑战,一是如何将光敏剂 ICG 和银纳米材料同时输送到肿瘤组织以增加癌症的治疗效果,二是如何开发一种开关去调控银离子的释放与 ICG 的剂量以增加治疗的安全性,三是如何提高其对肿瘤组织的靶向性并增强其在体内环境的稳定性。

近日,中国科学院苏州生物医学工程技术研究所检验室研究员董文飞课题组的王政等研究人员开发了一种叶酸多聚物修饰的 Janus 型银介孔二氧化硅纳米平台,并用于肝癌的协同治疗,有效解决了以上的 3 个难题。该纳米平台由银纳米球和介孔二氧化硅棒两部分组成,并且两部分在功能上互不干涉,可以极大地发挥银纳米球的离子释放功能以及介孔二氧化硅的药物运载工作。此外,Janus 型银介孔二氧化硅纳米载体展现了极好的 ICG 运载能力,可以在近红外的刺激下响应性地持续释放 ICG 并产生极好的热效应。热效应不仅可以用于抑制肿瘤组织的生长,还可以进一步促进了银球释放银离子,从而提高该载药系统对肿瘤细胞的杀伤作用。在该纳米平台中,叶酸多聚物修饰在纳米载体表面,用于提高其生物稳定性和对肿瘤组织的靶向性。

研究人员通过实验,在细胞和动物水平上研究了该纳米平台对肝癌的治疗效果并对其生物安全性进行了评价。实验结果显示,Janus 型银介孔二氧化硅纳米载体具有均一的形貌和极好的稳定性。载药后的纳米粒子不仅展现了高的药物担载能力,且呈现了近红外光响应性 ICG 释放的特点。在细胞实验中,Janus 型银介孔二氧化硅纳米载药系统对人肝癌细胞的抑制率明显高于相同规格的介孔二氧化硅纳米载药系统,证明了银离子在该体系中起到了补充光热治疗杀死效果的作用。在动物水平,该纳米载药系统展现了极好的对肿瘤的抑制效果。通过 HE 染色和检测血清生化学指标,科研人员发现该纳米载药系统具有极高的生物安全性。据此,研究人员认为 Janus 银介孔二氧化硅纳米载药系统是一种高效安全的抗肿瘤纳米平台。

相关研究成果发表在 ACS Appl. Mater. Interfaces. 上。


图 1. 构建 Janus 型银介孔二氧化硅纳米载药平台用于实现近红外调控的肝癌的化疗光热协同治疗示意图。


图 2.Janus 银介孔二氧化硅纳米粒子的细胞内吞和细胞毒性分析。a,共聚焦分析 3h 后 SMMC-7721 细胞对叶酸修饰的银介孔二氧化硅纳米粒子和银介孔二氧化硅纳米粒子的内吞;b,流式细胞仪定量分析细胞对纳米粒子的摄入行为;c,纳米粒子对 SMMC-7721 细胞的细胞毒性;d,纳米粒子对 SMMC-7721 细胞的细胞毒性。结果表明,银介孔二氧化硅纳米粒子可以进入细胞,通过表明在载体表面修饰叶酸,可以增加肿瘤细胞对纳米粒子的摄入行为。该纳米载药系统的细胞毒性呈剂量依赖性,安全剂量为 50μg/mL。


图 3. 体内水平评价该载药系统的抗肿瘤作用效果。a,肿瘤生长曲线;b,肿瘤照片;c,肿瘤重量;d,TUNEL 荧光染色照片;e,定量分析肿瘤组织中细胞的凋亡率。实验结果表明,该纳米载药系统具有极好的抗肿瘤效果。

原始出处:

Zheng Wang, et al. Janus Silver/Silica Nanoplatforms for Light-Activated Liver Cancer Chemo/Photothermal Therapy. ACS Appl. Mater. Interfaces, 2017, 9 (36), pp 30306–30317, DOI: 10.1021/acsami.7b06446.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804662, encodeId=fbfd1804662d6, content=<a href='/topic/show?id=7cffe746245' target=_blank style='color:#2F92EE;'>#纳米载药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77462, encryptionId=7cffe746245, topicName=纳米载药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Dec 14 05:53:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801238, encodeId=2e3118012385b, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Nov 01 21:53:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956671, encodeId=2bd919566e11f, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Apr 29 04:53:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655831, encodeId=bd3a16558313d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 23 03:53:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279229, encodeId=96bc12e92292b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Feb 01 12:53:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283978, encodeId=f3302839e806, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Jan 31 22:38:38 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283644, encodeId=bf5228364422, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Jan 30 22:50:34 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804662, encodeId=fbfd1804662d6, content=<a href='/topic/show?id=7cffe746245' target=_blank style='color:#2F92EE;'>#纳米载药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77462, encryptionId=7cffe746245, topicName=纳米载药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Dec 14 05:53:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801238, encodeId=2e3118012385b, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Nov 01 21:53:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956671, encodeId=2bd919566e11f, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Apr 29 04:53:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655831, encodeId=bd3a16558313d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 23 03:53:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279229, encodeId=96bc12e92292b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Feb 01 12:53:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283978, encodeId=f3302839e806, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Jan 31 22:38:38 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283644, encodeId=bf5228364422, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Jan 30 22:50:34 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804662, encodeId=fbfd1804662d6, content=<a href='/topic/show?id=7cffe746245' target=_blank style='color:#2F92EE;'>#纳米载药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77462, encryptionId=7cffe746245, topicName=纳米载药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Dec 14 05:53:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801238, encodeId=2e3118012385b, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Nov 01 21:53:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956671, encodeId=2bd919566e11f, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Apr 29 04:53:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655831, encodeId=bd3a16558313d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 23 03:53:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279229, encodeId=96bc12e92292b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Feb 01 12:53:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283978, encodeId=f3302839e806, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Jan 31 22:38:38 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283644, encodeId=bf5228364422, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Jan 30 22:50:34 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804662, encodeId=fbfd1804662d6, content=<a href='/topic/show?id=7cffe746245' target=_blank style='color:#2F92EE;'>#纳米载药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77462, encryptionId=7cffe746245, topicName=纳米载药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Dec 14 05:53:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801238, encodeId=2e3118012385b, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Nov 01 21:53:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956671, encodeId=2bd919566e11f, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Apr 29 04:53:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655831, encodeId=bd3a16558313d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 23 03:53:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279229, encodeId=96bc12e92292b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Feb 01 12:53:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283978, encodeId=f3302839e806, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Jan 31 22:38:38 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283644, encodeId=bf5228364422, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Jan 30 22:50:34 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-02-23 shanyongle
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804662, encodeId=fbfd1804662d6, content=<a href='/topic/show?id=7cffe746245' target=_blank style='color:#2F92EE;'>#纳米载药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77462, encryptionId=7cffe746245, topicName=纳米载药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Dec 14 05:53:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801238, encodeId=2e3118012385b, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Nov 01 21:53:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956671, encodeId=2bd919566e11f, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Apr 29 04:53:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655831, encodeId=bd3a16558313d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 23 03:53:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279229, encodeId=96bc12e92292b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Feb 01 12:53:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283978, encodeId=f3302839e806, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Jan 31 22:38:38 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283644, encodeId=bf5228364422, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Jan 30 22:50:34 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-02-01 yaanren
  6. [GetPortalCommentsPageByObjectIdResponse(id=1804662, encodeId=fbfd1804662d6, content=<a href='/topic/show?id=7cffe746245' target=_blank style='color:#2F92EE;'>#纳米载药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77462, encryptionId=7cffe746245, topicName=纳米载药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Dec 14 05:53:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801238, encodeId=2e3118012385b, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Nov 01 21:53:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956671, encodeId=2bd919566e11f, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Apr 29 04:53:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655831, encodeId=bd3a16558313d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 23 03:53:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279229, encodeId=96bc12e92292b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Feb 01 12:53:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283978, encodeId=f3302839e806, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Jan 31 22:38:38 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283644, encodeId=bf5228364422, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Jan 30 22:50:34 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-01-31 131****2916

    不错的文章值得推荐

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1804662, encodeId=fbfd1804662d6, content=<a href='/topic/show?id=7cffe746245' target=_blank style='color:#2F92EE;'>#纳米载药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77462, encryptionId=7cffe746245, topicName=纳米载药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Dec 14 05:53:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801238, encodeId=2e3118012385b, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Nov 01 21:53:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956671, encodeId=2bd919566e11f, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Apr 29 04:53:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655831, encodeId=bd3a16558313d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 23 03:53:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279229, encodeId=96bc12e92292b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Feb 01 12:53:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283978, encodeId=f3302839e806, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Jan 31 22:38:38 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283644, encodeId=bf5228364422, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Jan 30 22:50:34 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-01-30 1e1b8538m79(暂无匿称)

    不错的文章.值得拥有

    0

相关资讯

全球针对肝癌的PD-1抗体获FDA批准,奋起直追,国产PD-1抗体顺利进入三期临床

作为一项严重的全球性健康问题,肝癌(HCC)是癌症相关死亡率的第二大原因,肝癌(HCC)难治已是众所周知!全球每年约有782,000例新发病例,造成的死亡人数约为746,000例。而中国约占全球新发HCC病例和HCC相关死亡人数的50%。也就是说,全世界几乎一半的肝癌患者都在中国。此外,国内大部分的肝癌患者,发现就是晚期,没有了手术的机会。但就目前来看,治疗晚期肝癌的药物并不多,对于这类患者来说,

NPJ Precis Oncol:维生素C优先杀死“吃货”肿瘤干细胞!

2018年1月8日海军军医大学东方肝胆外科医院王红阳院士研究团队在《自然》子刊《npj-肿瘤精准医疗》上发表重磅文章,该研究发现维生素C优先杀死肝癌的肿瘤干细胞并改善患者预后。

秦叔逵教授:肝癌精准治疗需要加油,药物安全性值得关注

精准医学运用于肿瘤领域方兴未艾,但是在不同的瘤种和阶段,发展速度和程度参差不齐。近来,许多重要会议上都有关于精准医学,包括分子靶向和免疫治疗研究的新数据出炉,临床肿瘤专家不仅关注药物的有效性,也开始重视药物的安全性。

Radiology:钆塞酸增强MRI与扩散加权MR成像特点在识别细胞角蛋白19阳性肝细胞肝癌的价值

本研究旨在前瞻性验证磁共振成像(MRI)表现在预测角蛋白19(CK19)阳性肝细胞肝癌(HCC)的价值,评价单发CK19阳性患者较阴性患者切除性治疗的预后差异,并将结果发表在Radiology上。

樊嘉领队9年攻关 肝癌诊治诞生两项“全球首例”

中山医院院长樊嘉教授,副院长周俭教授领衔团队,在肝癌诊治领域实现两项重大研发成果。

Mol Clin Oncol:肝癌TACE术后早期应用索拉非尼可增加局部控制?

近期,来自日本鹿儿岛大学的Tamai T等人开展了一项前瞻性研究,旨在评价索拉非尼对于经肝动脉化疗栓塞(TACE)治疗后的不可切除肝细胞癌(HCC)的疗效,相关研究近日发表在Mol Clin Oncol杂志。